Discussion
Persons with Down syndrome have an increased risk of developing keratoconus.17–19 Our literature search identified several studies that have reported increased rates in this population–in one study as high as 71%.31 However, previous studies vary greatly; furthermore, their estimates have primarily been based on small sample sizes and often on selected hospital populations or children.13 15 16 18–30 Only one study reported nationwide numbers, estimating a keratoconus prevalence of 5.5% among persons with Down syndrome.34
Most previous studies have estimated a keratoconus prevalence in the range of 17.5–86 per 100 000 in general populations.2 38–42 However, markedly higher numbers have been reported in some recent studies of general populations, with an estimated prevalence of 0.2% in Norway,4 0.3% in the Netherlands3 and 1.2% in a younger population in Australia.7 Furthermore, even higher rates have been found in subgroups of the population in India, Jerusalem, New Zealand and Saudi Arabia.5 6 43 44 Although knowledge is limited concerning the aetiology of keratoconus, a number of publications have indicated that specific conditions are associated with an increased risk, including atopy, allergy, eye rubbing, Leber’s congenital amaurosis, mitral valve prolapse and connective tissue disease.17 45 46 In addition, an association with Down syndrome has been clearly demonstrated.17–19
Down syndrome is caused by an extra copy of chromosome 21. The occurrence seems to vary across countries, in the range of 0.7–1.4 per 1000 live births.47 48 The proportion in the general population is expected to be slightly lower, as persons with Down syndrome have a shorter life expectancy.49 50 Rates of approximately 0.8 per 1000 people in the general population have been reported.49 51 Suggested links with keratoconus are collagen-related abnormalities and that keratoconus is linked to chromosome 21.17 45 Additionally, it has been argued that Down syndrome is associated with more eye rubbing and possibly also a higher frequency of atopy.15 17 30 45 52 Moreover, a thinner cornea has been found in the eyes of persons with Down syndrome without manifest keratoconus.15 16
This literature review identified studies that have reported keratoconus in as many as 8%–36% of persons with Down syndrome15 16 18 22 23 27–30 33 and in one study even in 71%.13 However, several of these studies had small sample sizes and a biased patient selection (table 1). Furthermore, other studies have reported no keratoconus in persons with Down syndrome.19 20 25 26 This inconsistency is likely due to study design, completeness of the data, disease criteria, the diagnostics used and ethnicity (it has been speculated that the proportion of keratoconus is considerably lower in Asians with Down syndrome).53 In addition, age seems to be an important factor to the variation in prevalence, as several of the studies (especially those from Asia) seem to have only included children, whereas keratoconus usually develops in adolescence or early adulthood. Furthermore, corneal topography was not always included as part of the ocular examination. This review identified rates in the range of 10.6%–71.3% in studies that included corneal topography as part of the examination of mainly adult patients (table 1).13 15 16 22 23 27 31 32
In a study from Norway, we reported a national prevalence of keratoconus in persons with Down syndrome using data from a nationwide patient registry,34 thereby avoiding the risk of selection bias. We found a keratoconus rate of 5.5% in this subgroup, which is 30 times the estimated keratoconus prevalence in the general Norwegian population.4 The Norwegian Patient Registry is nationwide and mandatory for public specialist care; thus, making it possible to study the national occurrence of keratoconus in persons with Down syndrome and compare it with the corresponding rate in the general population. However, even in national register studies, some uncertainty remains as to whether patients have been correctly coded. In addition, the true prevalence of keratoconus in patients with Down syndrome is probably higher, as no routine screening is performed for this condition.
Few other studies of keratoconus in persons with Down syndrome have been carried out in Northern Europe.15 16 18 A case–control study by Haugen et al15 found a thinner cornea, higher keratometry values and more keratoconus in the Down syndrome group, as 5 out of 47 (11%) individuals with Down syndrome had keratoconus, compared with 1 out of 51 (2%) controls. In studies from various other regions throughout the world, lower proportions than the one we found in Norway have been reported in young patients,20 24–26 whereas higher proportions have often been reported in selected hospital populations.13 18 22 28 29 In a study from Brazil, Bermudez et al31 reviewed the medical records of 1207 patients with Down syndrome and found a keratoconus rate of 27.2%. They describe an ophthalmological outpatient clinic for Down syndrome patients, which included corneal topography if keratoconus was suspected and the patient cooperated. Thus, their numbers possibly approaches a realistic prevalence if screening for keratoconus is performed in persons with Down syndrome.
It seems reasonable to suspect a substantial number of undiagnosed cases of keratoconus, particularly in persons with Down syndrome, since the detection of this eye condition depends on adequate communication of symptoms, timely referral and good cooperation during the eye examinations. Early keratoconus may be challenging to diagnose in the slit lamp only, and cooperation with corneal tomography is often a challenge in persons with Down syndrome. Retinoscopy may be valuable by searching for abnormal motions of the retinoscopy reflex.15
Several studies from general populations have found a male predominance for keratoconus,3 6 40 54–56 although this finding has not been consistent.2 5 39 57 In this literature review, we identified one publication that found a similar gender distribution among persons with Down syndrome and keratoconus,22 which is consistent with our recent publication,34 otherwise, the gender distribution does not seem to have been in focus. There seem to be slightly more male than female persons with Down syndrome.50 58 We were, therefore, surprised to find a similar gender distribution for keratoconus in persons with Down syndrome in our study from Norway, as we have previously identified a quite pronounced male predominance for keratoconus in general in the total Norwegian population.4 Several predisposing factors seem to influence the development of keratoconus, and we hypothesise that the predominant factor in persons with Down syndrome is not related to gender or hormonal factors. However, this is speculation, and further research is needed.
Results from this literature review indicate a considerably higher proportion of keratoconus in persons with Down syndrome compared with the general population. An implication from this finding is that screening should be considered for this group,30 59 especially since several of these patients are less able to communicate their symptoms. Health economic aspects should be included in such evaluations. Marsack et al27 demonstrated keratoconus suspect findings in 11.8%–20.8% of eyes of persons with Down syndrome, using two detection metrics on corneal topographies. If keratoconus is detected, and CXL treatment is performed in early stages, a good visual acuity can hopefully be maintained. Furthermore, this may avoid persons reaching advanced stages, where corneal transplantation with a long postoperative follow-up may become necessary; a treatment that is particularly complicated in Down syndrome patients.60 A considerable proportion of persons with Down syndrome has visual impairment,21 and advanced stage keratoconus is likely one of the reasons.
In conclusion, the present review found a great variation in the reported prevalence of keratoconus in persons with Down syndrome; however, most studies of adolescents and adults reported a markedly higher prevalence than in the general population. Still, it seems likely that a significant number of keratoconus cases in persons with Down syndrome are undiagnosed. This indicates that screening for keratoconus in these individuals should be considered, to detect candidates for CXL treatment at an early stage. Also, large screening studies in persons with Down syndrome using slit lamp examinations and corneal tomography in cooperative individuals could provide more answers regarding the true prevalence.